ProMetic Sells Biotech Product in China

ProMetic Life Sciences, a Montreal-area biopharma, has made its first sale in China. The company said an unnamed large China pharma purchased a proprietary Mimetic Ligand™ affinity adsorbent to be used in a biomanufacturing process, which it will use for scale-up manufacturing of a biosimilar. If the biosimilar product is eventually approved, ProMetic expects a long-term supply agreement could yield the company between $3 million and $5 million per year. More details.... Stock Symbol: (TSX: PLI)     Share this with colleagues: